The shorters are making a mockery of the Analyst's prognostications.
Not sure why you'd wait for results to decide whether to buy more. You won't get these shares this cheap in the near future. EPP is passé, vitiligo is the level up. Even if the sp settled back to ~$30 only on vitiligo approval that's almost triple and is closer to a fairer valuation than the garbage we've seen in recent times. $30 doesn't include the future earnings of vitiligo, call it a reset of expectations. Add vitiligo revenue to this and we'll start seeing those long lusted after valuations, I can't see vitiligo being denied judging by the recent photos.
You get your triple, then the rest is on top.
CUV Price at posting:
$11.21 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)